<DOC>
	<DOCNO>NCT02467569</DOCNO>
	<brief_summary>The purpose study assess pharmacokinetics，safety tolerability Hemay020 determine recommend dose future Phase II study well obtain preliminary information efficacy Hemay020 subject solid tumor . The study conduct two part . Part one , test do 16-31 subject determine safety tolerability Hemay 020 patient advance solid tumor . Part two , another 16-24 subject advance metastatic NSCLC , add trial well define tolerability preliminary efficacy Hemay020 .</brief_summary>
	<brief_title>Study Evaluating Hemay020 In Subjects With Advanced Solid Cancer</brief_title>
	<detailed_description>This phaseⅠsequential-group study ascend single multiple oral dos administer subject advance solid tumor . Each subject receive single dose Hemay020 , follow 2-week observation period , receive Hemay020 administer daily mouth 28 day . Each cycle consist 28 day . Subjects enrol group 3 6 . Depending safety activity profile observe dose escalation phase , dose select Part 2 may adjust . Part 2 extension part two dose group administer subject NSCLC .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>1 . Male female subject age 18 70 year ; 2 . Subjects histologically cytologically confirm diagnosis solid tumor ; subject fail standard therapy，or effective therapy available patient ; 3. least one measurable tumour lesion ( non radiation field ) define RECIST criterion measure CT MRI technique ; 4 . Patients receive chemotherapy least 4 week prior screen must recover toxic effect treatment CTCAE≤Grade 1 ; 5 . Part 1 Only : ECOG Performance Status 0,1 ; 6 . Life expectancy least three ( 3 ) month ; 7 . Adequate bone marrow , liver , kidney coagulation function , meet follow criterion : ANC≥1.5×109/L，HB≥90g/L，PLT≥75×109/L； TBIL≤2×ULN； ALT≤2.5×ULN，AST≤2.5×ULN（ALT≤5×ULN，AST≤5×ULN liver metastasis present） Serum creatinine≤1.5×ULN INR≤1.5×ULN Patients without gastrointestinal tract disease , result malabsorption syndrome , patient unable take oral medication ; 8 . All female male subject must agree commit use two contraceptive regimen duration study 6 month last dose test article . Female subject must negative serum urine pregnancy test perform within 72 hour prior treatment . Male subject 's sexual partner must use two contraceptive regimen . Two contraceptive regimen include medication nonmedication contraceptive regimen ; 9 . Able understand sign write informed consent study entry ; Inclusion Criteria Part 2 Only : 10 . Histological cytological diagnosis EGFR wildtype ( genetype determine ) patient , advance metastatic lung cancer receive two chemotherapy ; advanced metastatic patient EGFR mutation receive EGFRTKI one chemotherapy . 11 . ECOG Performance Status 0,1,2 Exclusion Criteria： 1 . Patients parenteral nutrition ; malabsorption syndrome ; condition possibly affect drug absorption inability tolerate oral medication ; 2 . Immunodeficiency history , include human immunodeficiency HIV positive（by ELISA Western Blot） ; 3. clinically QTc prolongation , ventricular tachycardia , ventricular fibrillation , heart block , myocardial infarction within 1 year , congestive heart failure , symptom require medicine treatment patient coronary heart disease ; 4 . Left ventricular ejection fraction ( LVEF ) &lt; 40％ ; 5. active infection ( ie , require intravenous antibiotic antiviral agent ) ; 6 . Organ system status : Patients brain metastasis untreated surgical resection radiotherapy , Patients treat brain metastasis may exclude neurologically unstable steroid receive steroid le 4 week prior study ; Patients bone marrow metastasis ; Documented history interstitial lung disease , drug induce interstitial lung disease , radiation pneumonitis steroid treatment , evidence clinically active interstitial lung disease ; Idiopathic fibrosis lung CT scan study entry ; Presence clinically significant uncontrolled disease ( ie . unstable uncompensated respiratory , heart , liver , kidney disease ) investigator 's judgment ; Any unstable systemic disease ( include severe hypertension , unstable angina , congestive heart failure , liver kidney metabolic disease ) Any malignant cancer within 5 year exception adequately treat cervical cancer situ basal squamous cutaneous cell carcinomas Neurological psychogenic disorder , include epilepsia dementia ; 7 . Major surgery ( include biopsy ) injury within 4 week treatment day 1 ; 8 . History alcohol drug abuse ; 9 . Women pregnant breast feed plan pregnant ; 10 . Pulse rate &lt; 40 per minute &gt; 120 per minute ; systolic pressure＞140mmHg diastolic pressure＞90mmHg ; axillaty temperature ≥37.1℃ oral temperature ≥37.3℃ ; 11 . Have know hypersensitivity test article excipient test article ; 12 . Have receive clinical trial treatment within last 3 month time study ; 13 . History herbal ingredient , depressant , hypnotic drug abuse ; 14 . Evidence significant medical illness abnormal laboratory find would make subject inappropriate study investigator 's judgment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>